Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LifeVantage Co. stock logo
LFVN
LifeVantage
$13.39
+6.2%
$13.92
$5.22
$27.38
$168.55M0.41140,539 shs152,364 shs
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$3.24
+20.0%
$3.07
$1.45
$19.50
$107.56M1.27481,394 shs1.74 million shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.39
+3.4%
$3.07
$2.23
$4.83
$168.25M1.29441,553 shs810,400 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.86
+7.4%
$0.76
$0.62
$1.70
$44.50M-0.271.38 million shs828,119 shs
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LifeVantage Co. stock logo
LFVN
LifeVantage
0.00%+9.13%-0.30%-27.86%+87.01%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
0.00%+20.45%+19.56%-28.00%-76.79%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.00%+16.49%+18.53%+18.53%-27.10%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
0.00%+21.04%+14.34%-24.61%-23.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LifeVantage Co. stock logo
LFVN
LifeVantage
4.0968 of 5 stars
3.51.01.72.72.71.71.3
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
2.8503 of 5 stars
3.62.00.00.02.22.51.3
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.703 of 5 stars
3.51.00.00.02.43.33.1
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
2.696 of 5 stars
3.55.00.00.00.60.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50127.78% Upside
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
3.17
Buy$20.20523.46% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.00106.49% Upside
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
3.00
Buy$4.00365.44% Upside

Current Analyst Ratings Breakdown

Latest XLO, PBYI, LFVN, and LXEO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $15.00
5/13/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $20.00
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$25.00 ➝ $22.00
4/8/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/26/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$24.00 ➝ $20.00
3/25/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/24/2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $18.00
2/28/2025
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.76$0.70 per share19.03$2.38 per share5.63
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
$650K165.47N/AN/A$4.26 per share0.76
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$232.71M0.72$0.81 per share4.19$1.12 per share3.03
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$9.27M4.80N/AN/A$1.34 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6923.91N/A3.46%34.29%15.04%N/A
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$66.39M-$3.30N/AN/AN/AN/A-57.66%-48.18%N/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$21.59M$0.777.068.92N/A9.56%41.60%10.71%N/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$76.40M-$0.84N/AN/AN/AN/A-211.50%-80.31%N/A

Latest XLO, PBYI, LFVN, and LXEO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.10-$0.18-$0.28-$0.18$42.00 million$2.93 million
5/12/2025Q1 2025
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.80-$0.99-$0.19-$0.99N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
3/24/2025Q4 2024
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
-$0.87-$0.78+$0.09-$0.78N/AN/A
3/11/2025Q4 2024
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$0.22-$0.20+$0.02-$0.20$2.26 million$1.72 million
2/27/2025Q4 2024
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$0.10$0.39+$0.29$0.39$52.50 million$59.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.34%N/A26.09%3 Years
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/AN/AN/AN/AN/A

Latest XLO, PBYI, LFVN, and LXEO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
0.01
5.95
5.95
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.46
1.42
1.40
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/A
1.67
1.67

Institutional Ownership

CompanyInstitutional Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
60.67%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
54.29%

Insider Ownership

CompanyInsider Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
4.50%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.70%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
Lexeo Therapeutics, Inc. stock logo
LXEO
Lexeo Therapeutics
5833.20 million31.58 millionNot Optionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million37.45 millionOptionable
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
7051.78 million41.67 millionNot Optionable

Recent News About These Companies

Xilio Therapeutics reports Q4 EPS (20c) vs (64c) last year
Xilio Therapeutics files $250M mixed securities shelf
AbbVie, Xilio Hook up
AbbVie expands oncology R&D with Xilio deal

New MarketBeat Followers Over Time

Media Sentiment Over Time

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$13.39 +0.78 (+6.19%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$13.78 +0.39 (+2.91%)
As of 05/16/2025 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Lexeo Therapeutics stock logo

Lexeo Therapeutics NASDAQ:LXEO

$3.24 +0.54 (+20.00%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$2.99 -0.25 (-7.72%)
As of 05/16/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.39 +0.11 (+3.35%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$3.39 0.00 (0.00%)
As of 05/16/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Xilio Therapeutics stock logo

Xilio Therapeutics NASDAQ:XLO

$0.86 +0.06 (+7.43%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$0.85 -0.01 (-1.09%)
As of 05/16/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.